Nuvation Bio (NUVB) Competitors $2.20 -0.07 (-2.86%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$2.26 +0.05 (+2.49%) As of 02/21/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NUVB vs. XENE, MOR, TWST, VCEL, CPRX, MLTX, MRUS, BEAM, IBRX, and ARWRShould you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include Xenon Pharmaceuticals (XENE), MorphoSys (MOR), Twist Bioscience (TWST), Vericel (VCEL), Catalyst Pharmaceuticals (CPRX), MoonLake Immunotherapeutics (MLTX), Merus (MRUS), Beam Therapeutics (BEAM), ImmunityBio (IBRX), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Nuvation Bio vs. Xenon Pharmaceuticals MorphoSys Twist Bioscience Vericel Catalyst Pharmaceuticals MoonLake Immunotherapeutics Merus Beam Therapeutics ImmunityBio Arrowhead Pharmaceuticals Nuvation Bio (NYSE:NUVB) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, community ranking, risk, media sentiment and institutional ownership. Do institutionals & insiders believe in NUVB or XENE? 61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 5.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 5.5% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts rate NUVB or XENE? Nuvation Bio currently has a consensus target price of $8.20, suggesting a potential upside of 271.88%. Xenon Pharmaceuticals has a consensus target price of $57.38, suggesting a potential upside of 44.41%. Given Nuvation Bio's higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Xenon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Is NUVB or XENE more profitable? Nuvation Bio's return on equity of -21.89% beat Xenon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Nuvation BioN/A -21.89% -17.86% Xenon Pharmaceuticals N/A -24.69%-23.68% Does the media favor NUVB or XENE? In the previous week, Xenon Pharmaceuticals had 5 more articles in the media than Nuvation Bio. MarketBeat recorded 7 mentions for Xenon Pharmaceuticals and 2 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.97 beat Xenon Pharmaceuticals' score of 0.67 indicating that Nuvation Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, NUVB or XENE? Nuvation Bio has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation BioN/AN/A-$75.80M-$2.17-1.02Xenon Pharmaceuticals$9.43M321.21-$182.39M-$2.82-14.09 Does the MarketBeat Community believe in NUVB or XENE? Xenon Pharmaceuticals received 372 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 80.00% of users gave Nuvation Bio an outperform vote while only 70.00% of users gave Xenon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNuvation BioOutperform Votes4880.00% Underperform Votes1220.00% Xenon PharmaceuticalsOutperform Votes42070.00% Underperform Votes18030.00% Which has more volatility and risk, NUVB or XENE? Nuvation Bio has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. SummaryNuvation Bio beats Xenon Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Nuvation Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUVB vs. The Competition Export to ExcelMetricNuvation BioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$764.01M$7.04B$5.84B$20.29BDividend YieldN/A2.75%4.75%3.64%P/E Ratio-1.026.1426.7934.92Price / SalesN/A267.56434.7817.43Price / CashN/A65.6738.0120.26Price / Book0.806.707.644.80Net Income-$75.80M$138.98M$3.19B$1.02B7 Day Performance-3.08%-2.63%-2.12%-1.07%1 Month Performance-20.25%-2.33%-0.45%-1.11%1 Year Performance23.88%-5.33%16.26%13.69% Nuvation Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUVBNuvation Bio2.0414 of 5 stars$2.21-2.9%$8.20+271.9%+24.6%$764.01MN/A-1.0260XENEXenon Pharmaceuticals2.7079 of 5 stars$38.91-0.9%$57.38+47.5%-19.3%$2.97B$9.43M-13.80210Options VolumeNews CoverageMORMorphoSys0.1236 of 5 stars$18.96flat$18.25-3.7%N/A$2.86B$238.28M-5.45730Positive NewsTWSTTwist Bioscience4.5944 of 5 stars$47.59+1.5%$53.80+13.0%+7.0%$2.84B$312.97M-14.08990Positive NewsVCELVericel2.939 of 5 stars$57.09+0.5%$63.14+10.6%+7.6%$2.82B$197.52M951.66300Positive NewsCPRXCatalyst Pharmaceuticals4.8589 of 5 stars$23.27+0.0%$32.25+38.6%+55.6%$2.78B$398.20M19.7280Upcoming EarningsMLTXMoonLake Immunotherapeutics2.0681 of 5 stars$43.21-0.9%$85.50+97.9%-19.0%$2.76BN/A-33.502News CoverageGap UpMRUSMerus2.9177 of 5 stars$40.20-0.2%$85.92+113.7%+0.2%$2.75B$43.95M-10.1837BEAMBeam Therapeutics3.125 of 5 stars$32.40+13.2%$47.67+47.1%-9.3%$2.68B$377.71M-18.41510Gap UpHigh Trading VolumeIBRXImmunityBio2.0686 of 5 stars$3.62+9.0%$13.58+275.2%-34.7%$2.52B$7.33M-3.93590News CoverageARWRArrowhead Pharmaceuticals4.0851 of 5 stars$19.95+4.4%$41.44+107.7%-34.1%$2.50B$3.55M-3.97400 Related Companies and Tools Related Companies Xenon Pharmaceuticals Alternatives MorphoSys Alternatives Twist Bioscience Alternatives Vericel Alternatives Catalyst Pharmaceuticals Alternatives MoonLake Immunotherapeutics Alternatives Merus Alternatives Beam Therapeutics Alternatives ImmunityBio Alternatives Arrowhead Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:NUVB) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
